Our Latest News - BUHLMANN

BUHLMANN News

BUHLMANN fCAL® turbo (calprotectin)

BÜHLMANN fCAL® turbo BÜHLMANN fCAL® turbo (K190784): FDA 510(k) cleared. For in vitro Diagnostic Use. BÜHLMANN fCAL® turbo + CALEX® Cap (K191718 & K232057): FDA 510(k) cleared. For in vitro Diagnostic Use. CPT Code: Calprotectin – 83993 fecal Calprotectin (fCAL)- An FDA Cleared Gastrointestinal Test to Distinguish IBD from IBS Calprotectin is a highly-sensitive clinical biomarker that has
Continue Reading

LabSense News Fall 2018 Edition

Continue Reading

IBDoc® Talk – Tips and Tricks Teleconference

Health Canada Licence: 98903, Device class: 3  BÜHLMANN IBDoc® is not available for sale in the US. IBDoc® is the first self-testing application for fecal calprotectin in IBD patients that involves three easy steps. IBDoc® allows IBD patients convenient self-testing of fecal calprotectin. Teleconference Overview Goal of Discussion The goal was for Clinical Administrators and Clinical Users from
Continue Reading

BUHLMANN Quantum Blue® fCAL Tutorial

View this demonstration of CALEX® Cap extraction and quantitative fecal calprotectin measurement using the Quantum Blue® fCAL rapid test technology. Quantum Blue® fCAL high range:  Health Canada License: 88674 Quantum Blue® fCAL: Health Canada License: 83477 US: (The Quantum Blue® tests are for Research Use Only. Not for use in diagnostic procedures in the US.) Contact BUHLMANN Today! Contact
Continue Reading

Early change in faecal calprotectin predicts primary non-response to anti-TNFα therapy in Crohn’s disease.

BÜHLMANN fCAL® ELISA Citation Pavlidis, P. et al., 2016, Early change in faecal calprotectin predicts primary non-response to anti-TNFα therapy in Crohn’s disease, Scandinavian Journal of Gastroenterology.  PMID: 27400728  DOI: 10.1080/00365521.2016.1205128 Highlight from this Publication “The ΔFCAL could act as an ‘early warning’ to consider alternatives such as dose optimisation or another biologic with a different mode of action,
Continue Reading

Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of a relapse: A prospective, randomized, controlled study.

BÜHLMANN fCAL® ELISA Citation Lasson, A. et al., 2014, Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of relapse: A prospective, randomized, controlled study, United European Gastroenterology Journal.  PMID: 25653861 DOI: 10.1177/2050640614560785 Highlight from this Publication “In patients with UC, FC-guided dosing of the patient’s 5-ASA agent showed significantly lower relapse rates than
Continue Reading

The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease

BÜHLMANN fCAL® ELISA Citation Zhulina, Y. et al., 2016, The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease, Aliment Pharmacol Ther.  PMID: 27402063 DOI: 10.1111/apt.13731 Highlight from this Publication “Our data suggest that longitudinal monitoring of faecal calprotectin is informative in predicting relapse in IBD.“ Read Citation BÜHLMANN fCAL® ELISA is FDA 510(k) cleared For in vitro Diagnostic
Continue Reading

Accuracy of Consecutive Fecal Calprotectin Measurements to Predict Relapse in Inflammatory Bowel Disease

Quantum Blue® fCAL Citation: Ferreiro-Iglesias, R., Barreiro-de Acosta, M., Lorenzo-Gonzalez, A. & Dominguez-Muñoz, J. E. Accuracy of Consecutive Fecal Calprotectin Measurements to Predict Relapse in Inflammatory Bowel Disease Patients Under Maintenance With Anti-TNF Therapy: A Prospective Longitudinal Cohort Study. J. Clin. Gastroenterol. (2016) PMID: remission, whereas concentrations >300 μg/g allow predicting relapse with a high probability at any
Continue Reading

Evaluation of S100 Proteins As Potential Biomarkers of Global and Renal-Specific Disease Activity in Childhood-Onset Systemic Lupus Erythematosus

BÜHLMANN sCAL ELISA: Turnier J et al.: Evaluation of S100 Proteins as Potential Biomarkers of Global and Renal-Specific Disease Activity in Childhood-Onset Systemic Lupus Erythematosus. Poster presented at ACR/ARHP, 2016: November 11-16, Washington, DC (USA). View Poster BÜHLMANN sCAL ELISA is for Research Use Only.  Not for use in diagnostic procedures in the US and
Continue Reading

Biomarkers as predictors of flares in inflammatory bowel disease

BÜHLMANN sCAL ELISA: Lavric M et al.: Biomarkers as Predictors of Flares in Inflammatory Bowel Disease. Poster presented at final MIAMI Meeting (Translating Science into targets); 2016: April 13-15, Muenster (Germany). View Poster BÜHLMANN sCAL ELISA is for Research Use Only.  Not for use in diagnostic procedures in the US and Canada.
Continue Reading

BÜHLMANN collaborates with Beckman Coulter

BÜHLMANN collaborates with Beckman Coulter for worldwide distribution of BÜHLMANN fCAL® turbo & fPELA® turbo assays on their clinical chemistry analyzers (AU480, AU680, AU5800, DxC 700 AU).

Learn More

This will close in 20 seconds